Expert Opinion on Drug Safety, Journal Year: 2023, Volume and Issue: 23(7), P. 937 - 948
Published: Nov. 30, 2023
Background The current investigation sought to conduct a real-world analysis of adverse events (AEs) associated with selexipag by utilizing data from the Food and Drug Administration Adverse Event Reporting System (FAERS).
Language: Английский
Reviews in Medical Virology, Journal Year: 2023, Volume and Issue: 33(2)
Published: Jan. 4, 2023
The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. This meta-analysis aimed determine efficacy of anakinra on mortality in patients with COVID-19. A systematic search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Randomized controlled trials treatment COVID-19 anakinra, compared placebo or blank, were reviewed. Studies pooled risk ratios (RRs), 95% confidence intervals (CIs). Five (enrolling 1859 participants) met inclusion criteria. There no statistically significant difference 14-day (RR 0.78, CI 0.43-1.39; P = 0.40), 28-day 1.06, 0.89-1.26; 0.51), 90-day 1.01, 0.73-1.39; 0.97) between two groups. Sensitivity analyses further confirmed these results. Anakinra not associated reduced hospitalised probably should be used routinely patients.
Language: Английский
Citations
11
Respiratory Research, Journal Year: 2023, Volume and Issue: 24(1)
Published: Nov. 1, 2023
Abstract Background Pulmonary arterial hypertension (PAH), Group 1 pulmonary (PH), is a type of vascular disease characterized by abnormal contraction and remodeling the arterioles, manifested resistance (PVR) increased pressure, eventually leading to right heart failure or even death. The mechanisms involved in this process include inflammation, matrix remodeling, endothelial cell apoptosis proliferation, vasoconstriction, smooth muscle proliferation hypertrophy. In study, we review action prostaglandins their receptors PAH. Main body PAH-targeted therapies, such as endothelin receptor antagonists, phosphodiesterase 5 inhibitors, activators soluble guanylate cyclase, prostacyclin, prostacyclin analogs, improve PVR, mean six-minute walk distance, cardiac output exercise capacity are licensed for patients with PAH; however, they have not been shown reduce mortality. Current treatments PAH primarily focus on inhibiting excessive recalcitrant currently available therapies. Lung transplantation remains definitive treatment Therefore, it imperative identify novel targets improving Studies confirmed that play important roles occurrence development through migration, extracellular remodeling. Conclusion Prostacyclin related drugs used clinical Other also potential treat This provides ideas discovery new drug targets.
Language: Английский
Citations
11
Clinics, Journal Year: 2025, Volume and Issue: 80, P. 100638 - 100638
Published: Jan. 1, 2025
Language: Английский
Citations
0
Stem Cell Reviews and Reports, Journal Year: 2024, Volume and Issue: 20(4), P. 931 - 937
Published: March 1, 2024
Language: Английский
Citations
3
Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 175, P. 116787 - 116787
Published: May 23, 2024
Pulmonary hypertension (PH) is a cardiovascular disorder characterized by substantial morbidity and mortality rates. It chronic condition intricate pathogenesis uncontrollable factors. We summarized the pathological effects of estrogen, genetics, neuroinflammation, intestinal microbiota, metabolic reorganization, histone modification on PH. PH not only pulmonary vascular disease, but also systemic disease. The findings emphasize that onset exclusively confined to vasculature, consequently necessitating treatment approaches extend beyond targeting blood vessels. Hence, research mechanism limited target organs such as vessels, focuses exploring other fields (such modification).
Language: Английский
Citations
2
Complementary Therapies in Medicine, Journal Year: 2022, Volume and Issue: 72, P. 102907 - 102907
Published: Dec. 10, 2022
The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. Ozone therapy has long been used in treatment of a variety infectious diseases, probably through its antioxidant properties supply oxygen hypoxic tissues. This systematic review meta-analysis aimed determine efficacy ozone on mortality patients with COVID-19.A search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Prospective controlled trials COVID-19 ozone, compared placebo or blank, were reviewed. Studies pooled risk ratios (RRs) weighted mean differences (WMDs), 95% confidence intervals (CIs).Eight (enrolling 371 participants) met inclusion criteria. showed significant effects (RR 0.38, CI 0.17-0.85; P = 0.02), length hospital stay (WMD -1.63 days, -3.05 -0.22 days; polymerase chain reaction (PCR) positivity 0.07, 0.01-0.34; 0.001).Ozone significantly reduced mortality, PCR positivity, hospitalized COVID-19. should be considered for patients.
Language: Английский
Citations
9
European Journal of Clinical Investigation, Journal Year: 2023, Volume and Issue: 53(11)
Published: July 1, 2023
Abstract Background Macitentan has demonstrated its effectiveness in patients with pulmonary hypertension (PH), but safety, especially for long‐term use, needs to be further explored. This systematic review and meta‐analysis aimed determine the safety of use macitentan PH. Methods A search was made PubMed, Embase, Cochrane Library clinicaltrials.gov , without language restrictions. Randomised controlled trials (RCTs) on treatment PH macitentan, compared placebo, were reviewed. Estimated effects included studies pooled as risk ratios (RRs), 95% confidence intervals (CIs). Results Six RCTs (enrolling 1003 participants) met inclusion criteria. Anaemia (RR 3.86, CI 2.05–7.30), headache 1.52, 1.02–2.26) bronchitis 2.24, 1.30–3.87) more frequent groups. There no statistically significant difference proportion at least one adverse event (AE) or serious (SAE), AEs leading discontinuation study treatment, all‐cause death, right ventricular failure (RVF) peripheral oedema between two Conclusions The is safe PH, although a higher anaemia, bronchitis.
Language: Английский
Citations
3
Global Heart, Journal Year: 2023, Volume and Issue: 18(1), P. 58 - 58
Published: Oct. 26, 2023
Background: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). Methods: A search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment PH macitentan, compared placebo or blank, were reviewed. Studies pooled weighted mean differences (WMDs) risk ratios (RRs), 95% confidence intervals (CIs). Results: Six RCTs (enrolling 1,003 participants) met inclusion criteria. Macitentan showed significant effects 6-min walk distance (6MWD) (WMD 12.06 m, CI 2.12 21.99 m), vascular resistance (PVR) –186.51 dyn·s/cm–5, –232.72 –140.29 dyn·s/cm–5), artery pressure (mPAP) –3.20 mmHg, –5.93 –0.47 mmHg), N-terminal pro-brain natriuretic peptide (NT-proBNP) –232.47 ng/L, wCI –318.22 –146.72 ng/L), cardiac index 0.39 L/min/m2, 0.20 0.58 L/min/m2). Conclusion: significantly improved 6MWD, PVR, mPAP, NT-proBNP, PH. should be further validated
Language: Английский
Citations
2
Journal of Investigative Medicine, Journal Year: 2024, Volume and Issue: 72(6), P. 567 - 573
Published: May 15, 2024
This systematic review and meta-analysis aimed to determine the efficacy of inhaled corticosteroids (ICS) on mortality in patients with coronavirus disease-2019 (COVID-19). A search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) treatment COVID-19 ICS were reviewed. Studies pooled risk ratios (RRs), 95% confidence intervals (CIs). Eleven RCTs (enrolling 5832 participants) met inclusion criteria. There no statistically significant difference COVID-19-related death (RR 0.88, CI 0.38–2.04), all-cause 1.05, 0.49–2.23), invasive ventilation 1.26, 0.60–2.62) between two groups. not associated reduced COVID-19.
Language: Английский
Citations
0
Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 27 - 49
Published: Nov. 1, 2024
Language: Английский
Citations
0